Dr. Kenneth H. Shain, MD

Dr. Shain practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Shain's NPI, 1083809255, was assigned on September 11, 2007. Dr. Shain graduated from USF Health Morsani College of Medicine in 2006. Dr. Shain holds Florida license ME107261.

Dr. Shain's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Shain's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Shain to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shain practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Shain's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Shain is board certified in medical oncology by the American Board of Internal Medicine. Dr. Shain is licensed in Florida.

Dmand AI lists breast cancer, chronic leukemia, immune deficiency disease, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Shain treats.

CMS data shows 216 Medicare services from Dr. Shain across 4 procedure codes in 2024, for 178 Medicare patients. Medicare paid $17,518 for them.

CMS counts 178 Medicare patients who saw Dr. Shain in 2024. The largest group is 75 to 84, with 82 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shain's median patient age at 71, with 46% women.

In 2024, Dr. Shain wrote 868 Medicare Part D claims for 185 patients. 60% of them were for generic drugs. CMS names the drug for 767 of them, across 16 drugs with 11 or more claims each, at $7,366,691 in total drug cost. In 2023, CMS named 744 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Shain for performance year 2024, reported as part of a group. Dr. Shain accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shain as offering telehealth.

Dmand AI links 95 papers to Dr. Shain, published from 2003 to 2025. 2024 was the busiest year, with 8. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Drug Resistance, Neoplasm. Dr. Shain has published most often in Blood Cancer J. Dr. Shain's most frequent co-authors are Melissa Alsina, MD, Rachid C. Baz, MD and William Dalton, MD.

Dmand AI links Dr. Shain to 5 clinical trials, 3 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Hypoxia. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 465 general payments to Dr. Shain from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. Janssen Pharmaceuticals, Inc paid the most, $92,297. It also lists 1 research payment totaling $417 in 2017.

Dr. Shain graduated from USF Health Morsani College of Medicine in 2006.

Dr. Shain is in network with 8 carriers, including Excellus BlueCross BlueShield, United Healthcare and Humana. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.